Dr. Kyle Biggar named a 2026 recipient of the Carleton IP Impact Award
Dr. Kyle Biggar (Institute of Biochemistry) has been named a 2026 recipient of the Carleton IP Impact Award for co-developing DarwinAI, an artificial intelligence platform designed to accelerate peptide drug discovery. Developed through a collaborative research project with Dr. James Green (Department of Systems and Computer Engineering) and their co-supervised PhD student Dr. François Charih, the technology uses AI to design target-specific peptide drugs and predict drug safety profiles earlier in development — cutting time, costs, and reliance on animal testing. Now successfully commercialized through Ottawa-based startup NuvoBio, DarwinAI is already supporting the design of new peptide-based treatments, turning Carleton research into real-world impact.